Sligo biotech start-up Nektr secures €1m in funding Frank Boyle, CEO of Nektr Technologies. Image: WDC The start-up is developing a compound that could help in tackling antibiotic resistance in humans and animals. Nektr Technologies, a Sligo-based biotech start-up, has raised €1m in funding to bring its technology from trial stages to market. It is developing a synthetic antimicrobial compound that could make treatments like antibiotics more effective for humans and animals. Half of the funding round comes from the Western Development Commission (WDC), with other backers including Enterprise Ireland also investing. Nektr’s technology, called A3IS, is hoped to be able to combat against multi-drug resistant pathogens. The start-up is exploring the application of its compound in dermatological conditions, nasal decontamination and medical device coatings.